Stakeholders disagree over how to reform FDA’s advisory committee system
Regulatory NewsFerdous Al-Faruque
Advisory committeesApproval/marketing authorizationBiologics/ biosimilars/ vaccinesMedical DevicesPharmaceuticalsUnited StatesUS Food and Drug Administration (FDA)